TRACON Pharmaceuticals, Inc (TCON): Price-to-Projected Revenue Ratio
TRACON Pharmaceuticals is expanding its oncology presence by utilizing a clinical trial outsourcing model. The forward P/S valuation demonstrates price dynamics relative to future revenue, where 0.00 captures a new level. The protection of the ENVASARC platform limits competitors but requires capital expenditures for FDA approval. Pragmatic investor sentiment is currently focused on optimizing the company's biotech assets.
Summary analytical data breakdowns for TRACON Pharmaceuticals, Inc (TCON)
- current price and projected stock value:
- stock exchange capitalization data:
- book value of equity indicators:
- debt and solvency information:
Total Debt to Capital TRACON Pharmaceuticals|TCON - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital TRACON Pharmaceuticals|TCON - Company Cumulative Debt|Debt to Book Value TRACON Pharmaceuticals, Inc|TCON - Company Long-Term Debts|Company Current Liabilities TRACON Pharmaceuticals|Quick Ratio traconpharma.com
- business earnings and investment ratios data:
TCON - Net Financial Result|Projected Future Earnings TRACON Pharmaceuticals|TCON - Price to Earnings Ratio|Forward P/E Multiple TRACON|TCON - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TRACON Pharmaceuticals, Inc|TCON - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months TRACON Pharmaceuticals|TCON - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months traconpharma.com|TCON - Net earnings per one share growth for the current year|Earnings growth forecast for next year TRACON Pharmaceuticals
- sales and revenue data:
Initial company analysis:TRACON Pharmaceuticals, Inc. (TCON)
Forward P/S measures the market value of a company relative to projected revenue, determining the business's margin of safety and the speed at which investor confidence in future cash flows recovers. By analyzing the expected P/S metric on the GURU.Markets platform, an investor assesses the efficiency of the internal clinical trial model of TRACON Pharmaceuticals (TCON), which minimizes contractor costs and enhances the commercialization potential of its drugs.
Competitors of TRACON Pharmaceuticals
Forward P/S Multiple TEM (Tempus AI, Inc.)|Forward P/S Multiple Qiagen NV QGEN|IONS - Price-to-Projected Revenue Ratio|Forward Price to Sales RGEN (Repligen Inc.)|Avidity Biosciences (RNA) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple crisprtx.com|WGS (GeneDx) - Forward P/S Multiple|Forward P/S Multiple Ultragenyx Pharmaceutical Inc.|Forward P/S Multiple BEAM|Forward Price-to-Revenue Multiple Sarepta Corp SRPT|Forward P/S Multiple TWST (Twist Bioscience)|10xgenomics.com (TXG) - Market Cap to Future Revenue Ratio|NTLA: Forward Price-to-Revenue Multiple|STOK - Forward P/S Multiple|BLFS (BioLife Corp) - Forward Price-to-Revenue Multiple|WVE: Price to Expected Revenue Ratio|MAZE (Maze Therapeutics Inc) - Forward P/S Multiple|sionnatx.com (SION) - Market Cap to Expected Sales Ratio|Forward P/S Multiple PRME|Forward Price-to-Revenue Multiple Taysha Gene Therapies Inc TSHA|Forward P/S Multiple QURE (uniQure Corp)|Forward P/S Multiple MeiraGTx Corp MGTX|RGNX - Price-to-Projected Revenue Ratio|SLDB: Price-to-Projected Revenue Ratio|Ocugen (OCGN) - Price-to-Projected Revenue Ratio|PACB - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple BNTC|DSGN (Design Corp) - Price to Expected Revenue Ratio|Forward P/S Multiple RCKT|Forward Price-to-Revenue Multiple 4dmoleculartherapeutics.com FDMT|Price-to-Projected Revenue Ratio Lexeo Therapeutics, Inc. LXEO|Korro Bio Inc. (KRRO) - Market Cap to Future Revenue Ratio|EDIT - Price-to-Projected Revenue Ratio|SLN (Silence Therapeutics Corp) - Market Cap to Projected Revenue|PRQR: Forward P/S Multiple|Market Cap to Projected Revenue CDXS|Price-to-Projected Revenue Ratio Sangamo Therapeutics, Inc.|Market Cap to Projected Revenue NAUT (Nautilus Biotechnology Inc)|Forward P/S Multiple MGX|Forward P/S Multiple Precision BioSciences Inc. (DTIL)|Generation Bio - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio BOLD (boundlessbio.com)|XCUR - Price-to-Projected Revenue Ratio|Forward Price to Sales IMNN (Imunon, Inc.)|PHIO: Forward P/S Multiple|Mustang Bio (MBIO) - Forward P/S Multiple|RNAZ (TransCode Therapeutics Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Bionano (BNGO)|Price-to-Projected Revenue Ratio Applied DNA Sciences, Inc. (APDN)|BLUE - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio ImmunoPrecise Antibodies Ltd. IPA|OMGA: Market Cap to Projected Revenue|OMIC: Forward Price-to-Revenue Multiple|Forward Price to Sales RGLS (regulusrx.com)|Syros Pharmaceuticals, Inc. (SYRS) - Price-to-Projected Revenue Ratio|Future Price to Revenue TBIO (Telesis Bio Inc.)|UBX (Unity Bio) - Forward P/S Multiple
